Skip to content

KEEL KEEL Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price

Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$47.13+56.3%
WaFd, Inc. logo
WaFd, Inc.WAFD
$7.53+36.9%
WSFS Financial logo
WSFS FinancialWSFS
$0.00-100%
MSCI logo
MSCIMSCI
$665.73+16.9%
WSFS Financial logo
WSFS FinancialWSFS
$0.00-100%
The Travelers Companies logo
The Travelers CompaniesTRV
$152.72+8.0%

Other financials

Income statement

See full
Revenue$37.0M-22.4%
Gross profit-$26.3M-9,631%
Operating income-$98.4M-182%
Net income-$145.4M-162%
EPS (diluted)-$0.24-118%

Balance sheet

See full
Cash & equivalents$357.3M+827%
Total debt$591.0M
Total equity$419.1M-36.6%
Total assets$1.1B

Cash flow

See full
Operating cash flow-$64.7M-243%
CapEx$10.3M-76.2%
Free cash flow-$75.0M-20.6%

Valuation

See full
Market cap$3.99B

Profitability

See full
Gross margin-7.9%-2.8pp
Operating margin-37.8%+2.0pp
Net margin-52%+24.6pp
FCF margin-259.9%+201pp

Returns & leverage

See full
Return on equity-6.1%-2.5pp
Debt / equity1.4×
Current ratio9.6×

Where this comes from

Reported directly by KEEL in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue.

The official record: KEEL’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about KEEL's share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KEEL's share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price?
KEEL (KEEL) reported share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price of $0.93 in Q4 2025.
What is the long-term trend for KEEL's share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price?
Over 2 years (2023 to 2025), KEEL's share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price has grown at a -7.2% compound annual growth rate (CAGR), from $1.08 to $0.93.
What does share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price mean?
This metric reflects the weighted average exercise price of nonvested stock options granted to employees and directors as part of their compensation packages. It provides insight into the cost basis of equity incentives and the performance hurdles required for these options to be in-the-money. This is a key metric for evaluating the company's talent retention strategy and potential future dilution from equity-based compensation.